SANTA CLARA, Calif. — VahatiCor, a medtech company focused on transforming care for Coronary Microvascular Dysfunction (CMD), has closed a $23 million Series B financing round. The oversubscribed round was led by S3 Ventures, with participation from Intuitive Ventures and a strategic investor. The funding will support the ongoing SERRA-I early feasibility study, engineering advancements, and preparation for additional clinical studies, including plans for pivotal trials and regulatory engagement.
“Securing this financing round from this esteemed group of investors is a significant validation of our therapy value proposition and the quality of our team,” said Marwan Berrada-Sounni, Co-Founder of VahatiCor. “With this support, VahatiCor can continue executing the critical next phase of our strategy to advance A-FLUX through clinical studies and fulfill our mission of making this breakthrough therapy available to the millions suffering from Coronary Microvascular Dysfunction. We are proud and excited to work on an interventional treatment that aims to provide meaningful clinical benefit and symptom relief and improve the quality of life for millions of patients worldwide.”
CMD affects millions globally and is characterized by chronic angina, chest pressure, and discomfort, despite the absence of blockages in major coronary arteries. In the United States, an estimated 3 to 4 million people exhibit symptoms of myocardial ischemia without obstructive Coronary Artery Disease. CMD disproportionately affects women, who experience higher rates of major adverse cardiac events (MACE) and a two- to fourfold increased risk when coronary flow reserve is impaired. Current treatments provide limited relief, and no approved therapies directly improve coronary flow reserve. As a result, CMD patients often endure repeated hospital visits and extensive cardiac testing, similar to or exceeding that of patients with obstructive disease.
The A-FLUX Reducer System is a coronary sinus reducer designed to enhance myocardial perfusion. By creating a controlled narrowing of the coronary sinus, the device helps redistribute oxygenated blood flow to support and enhance cardiac perfusion, providing relief from angina symptoms. The system includes a repositionable, self-expanding device to address procedural safety and efficacy.
“We believe VahatiCor’s A-FLUX Reducer System represents a significant breakthrough for an enormous and underserved patient population in need of a true solution,” said Brian R. Smith, Managing Director at S3 Ventures. “The company’s unique approach leveraging a repositionable, self-expanding device provides a meaningful advantage in procedural safety and efficacy, positioning them to become the clear leader in coronary sinus therapy.”
“The high symptom burden of recurring angina, reduced exercise capacity, diminished quality of life, and psychological distress caused by delayed diagnosis demands more clinical awareness and effective therapies that prioritize the patient experience,” added Terri Burke, Senior Partner at Intuitive Ventures. “VahatiCor’s A-FLUX is exactly the type of life-changing, patient-centered innovation we aim to support. We are confident in the company’s ability to follow the clinical pathway necessary to bring this long-awaited option to market.”
VahatiCor is currently advancing the SERRA-I early feasibility study, which will enroll 30 patients across six clinical sites to assess the safety and efficacy of A-FLUX in individuals with persistent symptomatic CMD.
